Assessment of Serum Amylase, Lipase and Associated Factors Among Patients with Leishmaniasis Treatment with Sodium Stigbo Gluconate /Paramomycine Attending University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia

Abstract

Abstract Background: Leishmaniasis is a life-threatening parasitic disease next to malaria, which is responsible for the death of 50,000 patients annually. It has three major clinical stages including visceral, cutaneous and mucocutaneous leishmaniasis. The former one is called kala-azar. Eastern Africa, the second largest VL endemic area following the Indian subcontinent, contributes to the high global burden with 30,000� 40,000 new cases per year, of which Ethiopia, South Sudan and Sudan accounts the largest proportion from cases. In Ethiopia the most common leishmaniasis foci are Omo and Aba-Roba plains and the Woyto and Segen River valleys in the Southern Nations, Nationalities and Peoples� Regional State (SNNPR), metema and humera. From this Metemma, Humera, and the bordering of Sudan are areas where incidence mostly occurs. There are so many drugs for leishmaniasis including sodium stigbogluconate and paramomycine combined treatment are the option in Ethiopia. Objectives: To assess serum amylase and lipase and associated factors among patients taking sodium stigbogluconate/paramomycine combined drugs at University of Gondar comprehensive specialized hospital, Northwest Ethiopia 2020 G.C. Method:Institutional based cross-sectional study was conducted at Gondar University Comprehensive Specialized Hospital from February to September 2020 G.C. Convenient sampling technique was used. Those who fulfill inclusion criteria were included in the study with written informed consent. 5 ml of blood were taken by experienced health professional. Descriptive Data were presented by table, chart and graphs. Data were cleared, entered by Epi-data version 3.1 then transfer to STATA 14.1 SE version and for analysis paired t-test were used, for factors and multivariate regression were used. Result: paired t-test showed that there was a significance mean difference between serum pancreatic amylase and lipase before and after treatment. The serum amylase count showed statistically significant increase (P<0.001),after treatment serum amylase was 141.2911�.07whencompared to that of before treatment51.3333 �.475. Similarly, serum lipase count shows statistically significant increase (p<0.001), after treatment serum lipase was 123.942�.07 when compared to that of before treatment 37.1593�.81